% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Westphalen:300293,
      author       = {C. B. Westphalen$^*$ and L. Boscolo Bielo and P. Aftimos
                      and H. Beltran and M. Benary$^*$ and D. Chakravarty and M.
                      Collienne$^*$ and R. Dienstmann and A. El Helali and J.
                      Gainor and P. Horak$^*$ and C. Le Tourneau and C. Marchiò
                      and C. Massard and F. Meric-Bernstam and C. Pauli and G.
                      Pruneri and F. Roitberg and H. E. G. Russnes and D. B. Solit
                      and N. Starling and V. Subbiah and D. Tamborero and N.
                      Tarazona and C. Turnbull and J. van de Haar and F. André
                      and J. Mateo and G. Curigliano},
      title        = {{ESMO} {P}recision {O}ncology {W}orking {G}roup
                      recommendations on the structure and quality indicators for
                      molecular tumour boards in clinical practice.},
      journal      = {Annals of oncology},
      volume       = {36},
      number       = {6},
      issn         = {0923-7534},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2025-00746},
      pages        = {614-625},
      year         = {2025},
      note         = {2025 Jun;36(6):614-625},
      abstract     = {With an increased uptake of genomic profiling in clinical
                      practice and the evolving complexity of diagnostic
                      modalities, vast amounts of complex data need to be properly
                      interpreted and integrated into an individualised care plan.
                      To address these challenges, molecular tumour boards (MTBs)
                      have been widely established. As of today, no international
                      recommendations regulating the composition and workflows of
                      MTBs have been defined.ESMO's Precision Oncology Working
                      Group (POWG) established an international expert panel in
                      precision oncology and defined core areas of interest. After
                      several consultations and through an expert consensus
                      process, the group reached a consensus level for each
                      recommendation.The group defined five components in the MTB
                      process that are critical to its function and clinical use:
                      (i) the primary task of MTBs consists in providing
                      genomic-informed clinical recommendations, particularly for
                      cases exhibiting complex genomic alterations; (ii) to
                      achieve this, MTBs should encompass interdisciplinary
                      expertise, with key roles for oncologists with genomic
                      expertise, pathologists with molecular training and clinical
                      geneticists; (iii) MTBs' recommendations should be
                      documented in a structured report that includes
                      genomic-informed treatment strategies, management plans for
                      potential tumour-detected germline alterations and guidance
                      for additional genomic testing; (iv) structured follow-up
                      processes should be implemented for monitoring the clinical
                      effectiveness of MTBs recommendations and (v) finally, the
                      panel proposed quality indicators for operating MTBs,
                      including turnaround times for cases discussion and the
                      proportion of cases for which actionable recommendations and
                      clinical trial enrolments were successfully
                      implemented.These ESMO's POWG recommendations can serve as a
                      guidance and help to define quality standards for MTBs to
                      allow for harmonisation and to further expedite the
                      integration of precision oncology into clinical practice.},
      keywords     = {ESMO (Other) / MTB (Other) / molecular tumour boards
                      (Other) / precision medicine (Other) / precision oncology
                      (Other) / targeted therapy (Other)},
      cin          = {MU01 / BE01 / A420 / B340},
      ddc          = {610},
      cid          = {I:(DE-He78)MU01-20160331 / I:(DE-He78)BE01-20160331 /
                      I:(DE-He78)A420-20160331 / I:(DE-He78)B340-20160331},
      pnm          = {311 - Zellbiologie und Tumorbiologie (POF4-311)},
      pid          = {G:(DE-HGF)POF4-311},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40194904},
      doi          = {10.1016/j.annonc.2025.02.009},
      url          = {https://inrepo02.dkfz.de/record/300293},
}